Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Gynecologic Oncology|November 8, 2011
Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancerC I Nagel, F J Backes, E M Hade, et al.
Gynecologic Oncology|February 2, 2013
Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancerK S Rath, D Loseth, P Muscarella, et al.
Reproduction, Fertility, and Development|March 3, 2005
Genetics and imaging to assess oocyte and preimplantation embryo healthC M Warner, J A Newmark, M Comiskey, et al.
Gynecologic Oncology|January 16, 2020
Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancerK Bixel, M Vetter, B Davidson, et al.
Gynecologic Oncology|July 14, 2022
Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 studyD M O'Malley, G M Bariani, P A Cassier, et al.
Gynecologic Oncology|January 4, 2021
A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancerL R Duska, C N Krasner, D M O'Malley, et al.
Phytochemistry|June 26, 2001
Elucidation of new structures in lignins of CAD- and COMT-deficient plants by NMRJ Ralph, C Lapierre, J M Marita, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 20, 2025
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 studyR S Kristeleit, S Ghamande, A Lisyanskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trialB J Monk, M P Barretina-Ginesta, B Pothuri, et al.
Pageof 5